Official Journal of the Human Genome Organisation
Table 3 The distribution of renal function for each treatment arm for the subgroups of DD, ID and II patients
From: High dose Losartan and ACE gene polymorphism in IgA nephritis
Patients | Renal function | Treatment group | P-value * | |||
|---|---|---|---|---|---|---|
High dose ARB | Normal dose ARB | ACEI 20 mg | ACEI 10 mg | |||
DD | Improved | 4 (66.67%) | 0 (0%) | 2 (15.38%) | 2 (33.33%) | 0.183 |
Stable | 2 (33.33%) | 4 (80%) | 8 (61.54%) | 3 (50%) | ||
ESRF | 0 (0%) | 1 (20%) | 3 (23.08%) | 1 (16.67%) | ||
Total | 6 (100%) | 5 (100%) | 13 | 6 | ||
ID | Improved | 8 (40%) | 5 (31.25%) | 1 (4.55%) | 1 (5.56%) | 0.008 |
Stable | 10 (50%) | 8 (50%) | 13 (59.09%) | 14 (77.78%) | ||
ESRF | 2 (10%) | 3 (18.75%) | 8 (36.36%) | 3 (16.67%) | ||
Total | 20 (100%) | 16 (100%) | 22 (100%) | 18 (100%) | ||
II | Improved | 11 (31.43%) | 4 (16.67%) | 3 (10.34%) | 0 (0%) | 0.012 |
Stable | 17 (48.57%) | 14 (58.33%) | 18 (62.07%) | 8 (61.54%) | ||
ESRF | 7 (20%) | 6 (25%) | 8 (27.59%) | 5 (38.46%) | ||
Total | 35 (100%) | 24 (100%) | 29 (100%) | 13 (100%) | ||